跳至主要内容
临床试验/NCT04860141
NCT04860141招募中4 期

Efficacy of Preoperative Administration of Gabapentin in Managing Intraoperative and Postoperative Pain From Third Molar Extractions.

Loma Linda University1 个研究点 分布在 1 个国家目标入组 98 人开始时间: 2021年6月16日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
招募中
入组人数
98
试验地点
1
主要终点
opioid use

研究概览

简要总结

This study is a double-blind, randomized, prospective, placebo-controlled single-center clinical research study in which 600 mg of gabapentin or placebo will be administered 2 hours preoperatively to 49 patients each undergoing wisdom teeth extraction. We will measure intraoperative opioid use, severity of pain, the number of analgesics taken, and side effect profiles (e.g. nausea/vomiting, dizziness) at the following intervals, 4 hour, 8 hour, 12 hour, 24, and 72 hour post-procedure.

详细描述

Since the 1990s, the amount of prescribed opioids has begun growing. According to the Center for Disease Control, more than 130 people die every day due to opioid overdose. Many medical and surgical specialities have devised various methods to decrease opioid use with adequate pain control. One notable method is preoperative administration of gabapentin. Gabapentin, a prescribed medication, is an anticonvulsant medication used to treat partial seizures, neuropathic pain (e.g.

diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain), hot flashes, and restless legs syndrome . Various surgical specialties such as otolaryngology, plastics, general surgery, obstetrics/gynecology have tested the efficacy of gabapentin in reducing postoperative opioid usage without compromising pain control and the result is promising. However, this study has not been done in oral and maxillofacial surgery. The objectives of the study is to determine if preoperative administration of gabapentin can decrease intraoperative and postoperative use of opioid and provide adequate pain control when used with non-opioid pain regimen.

On the day of consultation visit, subjects will be screened and evaluated by oral and maxillofacial surgery residents. Those who meet the inclusion criteria will be enrolled in the study. They will then be randomly divided into following groups:

  • Group 1a: 49 subjects undergoing wisdom teeth extraction will be receiving 600mg gabapentin PO preoperatively
  • Group 1b: 49 subjects undergoing wisdom teeth extraction will be receiving placebo PO preoperatively.

A subject then will be given a small bag that contains either a gabapentin pill or a placebo pill depending on which group that he or she is assigned to. The subject will be asked to take 600mg of gabapentin or a placebo pill 2 hours prior to their procedure (vs. current standard of care is no pre-medication). On the day of the procedure, they will be accompanied by a guardian or a family member to the clinic. The Procedure will be done by a senior or a chief level resident with supervision of an attending surgeon. Intraoperative opioid use will be recorded on a standardized anesthesia sheet. All cases will include IV sedation that involves a concoction of fentanyl, midazolam, propofol, ketamine, and dexamethasone. The medications will be given in boluses depending on their weight but not necessarily strictly kg-based. For example, fentanyl will be given between 25 -50mcg, midazolam 2.5-5mg, propofol 10-40mg and ketamine 10-50mg. Local anesthesia with 2% lidocaine with 1:100,000 epinephrine will also be given after sedation. Additional doses of local anesthetic can be given if the patient experiences sharp pain. Additional doses of propofol and/or fentanyl can be given if the patient's systolic blood pressure increases by 10 mmHg or heart rate increases by 20 bpm acutely. All used anesthetics will be recorded. After the procedure, standard postoperative pain regimen will be prescribed including 28 tablets of ibuprofen 600mg PO q6h prn pain and 12 tablets of Norco 5/325mg PO q6h prn pain with an instruction to take Norco only when a subject is in severe pain (pain level greater than 7 out of 10). To assess the severity of pain and its impact on functioning, scientists developed Brief Pain Inventory from which Modified Brief pain inventory (MBPI) was created to better fit the need for our research; MBPI will not only ask the severity of pain but also the number of analgesics taken and side effect profiles (e.g. nausea/vomiting, dizziness) at the following intervals, 4 hour, 8 hour, 12 hour, 24, and 72 hour post-procedure. The patient is to turn in the MBPI form during their 1 week postoperative follow up visit. If for any reason, the patient misses the follow up appointment, we will try to reschedule their visit within 5 days. If the patient does not show up at all, our members will find out the reason for the no show and record it for the publication purpose.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Investigator)

盲法说明

  • Only the allocator knows the computer generated randomization scheme and this will be strictly controlled. The allocator will not be directly involved in the patient care.
  • The allocator will also pre-package a pill in a small bag so that a distributor does not know which medication is being given to the patient.
  • Gabapentin and placebo pills will be formulated by an investigational pharmacist to ensure both pills are identical in shape and form to further reduce bias.

入排标准

年龄范围
18 Years 至 59 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects must be at or older than
  • Screened body mass index (BMI) between 18-35 kg/m
  • American Society of Anesthesiologists Classification I and II.
  • Subjects must be willing and able to comply with protocol requirements.
  • Subjects must be able to understand the informed consent and must be able to sign a written informed consent form prior to the initiation of any study procedures.
  • A subject must have at least 1 partial or fully impacted third molar tooth removal.

排除标准

  • hypersensitivity to gabapentinoids;
  • history of chronic opioid or gabapentin usage (regular use of opioids >3 months)
  • history of recreational drug usage
  • a history or clinical manifestations of significant metabolic, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urologic, musculoskeletal, psychiatric, or immunologic disorder, any acute, clinically significant illness or condition within 14 days prior to Day
  • Patients with baseline pain.
  • Patients with any oral pathology will be excluded.
  • Pregnant or breastfeeding patients
  • An individual not legally competent to consent (e.g., incapacitated individuals, incompetents, minors)

研究组 & 干预措施

Gabapentin group

Experimental

The patient in this group will take gabapentin 600mg PO 2 hours prior to his or her surgery.

干预措施: Gabapentin 600mg (Drug)

Placebo group

Placebo Comparator

The patient in this group will take a placebo that looks like gabapentin PO 2 hours prior to his or her surgery.

干预措施: Placebo (Drug)

结局指标

主要结局

opioid use

时间窗: 72 hour postoperatively

assess the number of opioid pills (norco 5/325mg) taken postoperatively. #of pills that a patient takes.

intraoperative fentanyl use

时间窗: during the surgical procedure

assess amount of fentanyl given intraoperatively. mcg of fentanyl given in a case.

opioid use

时间窗: 4 hour postoperatively

assess the number of opioid pills (norco 5/325mg) taken postoperatively. #of pills that a patient takes.

opioid use

时间窗: 8 hour postoperatively

assess the number of opioid pills (norco 5/325mg) taken postoperatively. #of pills that a patient takes.

opioid use

时间窗: 12 hour postoperatively

assess the number of opioid pills (norco 5/325mg) taken postoperatively. #of pills that a patient takes.

opioid use

时间窗: 48 hour postoperatively

assess the number of opioid pills (norco 5/325mg) taken postoperatively. #of pills that a patient takes.

次要结局

  • Drowsiness(within 72 hour postoperatively)
  • pain interfering in mood(within 72 hours postoperatively)
  • Vomiting(within 72 hour postoperatively)
  • pain interfering in relations with other people(within 72 hours postoperatively)
  • pain interfering in sleep(within 72 hours postoperatively)
  • pain interfering in enjoyment in life(within 72 hours postoperatively)
  • pain control(72 hour postoperatively)
  • nausea(within 72 hour postoperatively)
  • Dizziness(within 72 hour postoperatively)
  • pain interfering in general activity(within 72 hours postoperatively)
  • pain interfering in normal work(within 72 hours postoperatively)
  • pain control(4 hour postoperatively)
  • pain control(8 hour postoperatively)
  • pain control(12 hour postoperatively)
  • pain control(24 hour postoperatively)
  • pain control(48 hour postoperatively)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验